Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
26 hedge funds and large institutions have $36.5M invested in Interpace Biosciences, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 4 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
2% less capital invested
Capital invested by funds: $37.1M → $36.5M (-$596K)
10% less funds holding
Funds holding: 29 → 26 (-3)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BNP Paribas Financial Markets
Paris,
France
| $34 | – | – | – |
|
27
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $5 | – | – | – |
|
|
KSC
28
Kendall Square Capital
San Francisco,
California
| – | -$2.54M | -5,265 | Closed |
|
|
WI
29
WHV Investments
San Francisco,
California
| – | -$219K | -454 | Closed |
|
30
Goldman Sachs
New York
| – | -$74K | -153 | Closed |
|
|
LMF
31
LMR Master Fund
Grand Cayman,
Cayman Islands
| – | -$58K | -120 | Closed |
|
IDXG Hedge Fund Activity: Q4 2013 in Review
26 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q4 2013, worth a combined $36.5M — down 1.6% from $37.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IDXG and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 9 added.
The largest buyer was Heartland Advisors, adding an estimated $1.43M. The largest seller was Kendall Square Capital, exiting entirely with an estimated $2.54M sold.
- 26 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q4 2013, down from 29 in Q3 2013.
- Funds reported $36.5M of Interpace Biosciences, Inc. Common Stock stock for Q4 2013, down 1.6% quarter-over-quarter.
- 2 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q4 2013 and 4 closed out, a net change of -2 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q4 2013 was Heartland Advisors, an estimated $1.43M added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q4 2013 was Kendall Square Capital, an estimated $2.54M sold.
Based on aggregated 13F filings for Q4 2013.